TiGenix provides update on proposed initial public offering in the United States

 PRESS RELEASE

TiGenix provides update on proposed initial public offering in the United States

Leuven (BELGIUM) - October 26, 2016, 23:00h CET - TiGenix NV (Euronext Brussels: TIG; the "Company"), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics from its proprietary platforms of allogeneic expanded stem cells, announced today the filing of an amendment to its registration statement on Form F-1 with the U.S. Securities and Exchange Commission for the proposed initial public offering in the United States of its American Depositary Shares ("ADSs"), initially filed on December 22, 2015. The amendment includes a revised syndicate of underwriters for the proposed offering. The number and price of the ADSs to be offered will be determined if and when the initial public offering is launched.

BofA Merrill Lynch and Cowen and Company are acting as joint book-running managers for the proposed offering. Canaccord Genuity Inc. is acting as lead manager and BTIG, LLC is acting as co-manager.

A registration statement relating to the ADSs has been filed with the U.S. Securities and Exchange Commission but has not yet become effective. The ADSs may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. The proposed offering of ADSs will be made only by means of a prospectus. TiGenix's ordinary shares are currently listed on Euronext Brussels.

A copy of the preliminary prospectus, when available, can be obtained from BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd floor, Charlotte, NC  28255-0001, Attn: Prospectus Department, Email: [e-mail] and from Cowen and Company LLC, c/o Broadbridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, by telephone at [phone] or by fax at [phone].

This press release is for information purposes only and does not constitute, and should not be construed as, an offer to sell or the solicitation of an offer to buy or subscribe to any securities of TiGenix NV, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is not permitted or to any person or entity to whom it is unlawful to make such offer, solicitation or sale. This press release is not for publication or distribution, directly or indirectly, in or into any state or jurisdiction into which doing so would be unlawful.